Umecrine Cognition AB
Company

Umecrine Cognition AB

Biotechnology Research Park, Se 12 employees
Employees
12

Umecrine Cognition AB Overview

Headquarters
Park, Se
Industry
Biotechnology Research
Employees
12
Founded
2000
Funding
2.6M
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About Umecrine Cognition AB

Umecrine Cognition is developing a completely new type of drug for neurological disorders in the brain that can occur as a result of a number of underlying diseases and lead to severely reduced cognition and alertness. The results from an internationally recognized clinical phase 2 study indicate that the company’s most advanced drug candidate, golexanolone, improves brain signaling and cognition and alertness in patients with hepatic encephalopathy. The continued development of golexanolone is initially focused on patient groups whose symptoms have arisen as a result of chronic liver diseases, but the mechanism of action is also relevant in a number of other indication areas. The results from an internationally recognized clinical phase 2 study indicate that the company’s most advanced drug candidate, golexanolone, improves brain signaling and cognition and alertness in patients with hepatic encephalopathy. The continued development of golexanolone is initially focused on patient groups whose symptoms have arisen as a result of chronic liver diseases, but the mechanism of action is also relevant in a number of other indication areas.

Umecrine Cognition AB Contact Details

People in AeroLeads
4

Umecrine Cognition AB Org Chart

Sample employees and titles
Name Title Contact
Magnus Doverskog SVP & Cso at Umecrine Cognition
View
Lars ÖQvist Senior Executive, Global Marketing
View
John Ohd CEO Modus Therapeutics/cso Karolinska
View
Hans Christopher "Hc" Toll
View

Employees by Management Level

Executive 1 profile
Senior / Lead 1 profile
Individual contributor 1 profile

Compare Similar Companies to Umecrine Cognition AB